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Abstract
The CRISPR (clustered regularly interspaced short palindromic repeats) mechanism
allows bacteria to adaptively defend against phages by acquiring short genomic
sequences (spacers) that target specific sequences in the viral genome. We propose a
population dynamical model where immunity can be both acquired and lost. The model
predicts regimes where bacterial and phage populations can co-exist, others where the
populations exhibit damped oscillations, and still others where one population is driven
to extinction. Our model considers two key parameters: (1) ease of acquisition and (2)
spacer effectiveness in conferring immunity. Analytical calculations and numerical
simulations show that if spacers differ mainly in ease of acquisition, or if the probability
of acquiring them is sufficiently high, bacteria develop a diverse population of spacers.
On the other hand, if spacers differ mainly in their effectiveness, their final distribution
will be highly peaked, akin to a “winner-take-all” scenario, leading to a specialized
spacer distribution. Bacteria can interpolate between these limiting behaviors by
actively tuning their overall acquisition probability.
Author Summary
The CRISPR system in bacteria and archaea provides adaptive immunity by
incorporating foreign DNA (spacers) into the genome, and later targeting DNA
sequences that match these spacers. The way in which bacteria choose spacer sequences
from a clonal phage population is not understood. Our model considers competing
effects of ease of acquisition and effectiveness against infections in shaping the spacer
distribution. The model suggests that a diverse spacer population results when the
acquisition rate is high, or when spacers are similarly effective. At moderate acquisition
rates, the spacer distribution becomes highly sensitive to spacer effectiveness. There is a
rich landscape of behaviors including bacteria-phage coexistence and oscillations in the
populations.
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Introduction
Bacteria and archaea can combat viral infections using innate mechanisms (e.g.,
abortive infection, surface exclusion and restriction modification systems) that are not
specific to particular threats [1–3]. Some species also exhibit an adaptive immune
system based on CRISPR (clustered regularly interspaced short palindromic repeats)
interference, which allows bacteria to specifically target and cleave exogenous genetic
material from previously encountered phages and other genetic elements [4–7]. The
system works by incorporating short (30–70 bp) sequences, dubbed “spacers”, into the
bacterial genome, in between repeated CRISPR elements (Fig. 1). The spacers are
acquired from the “protospacer” regions in the genome of infecting phage. CRISPR
Type I and II require the presence of a “protospacer adjacent motif” (PAM) upstream
of a protospacer for recognition by the CRISPR proteins [8]. The PAM sequence is
thought to play a role in the avoidance of auto-immune targeting [9]. While the PAM
and the first few nucleotides of the protospacer (the “seed” region) need to match
almost perfectly for CRISPR interference [6], there is significant tolerance to mutations
in the rest of the spacer [10].
Over the whole viral genome, there can be tens or hundreds of protospacers, and the
way in which the CRISPR acquisition mechanism selects between these is not fully
understood [11]. Experiments show that after several hours of exposure of bacteria to
phage, different spacers occur with different frequencies, with a handful being much
more abundant [12]. Importantly, many of the highly abundant spacers recur during
repetition of the experiments, suggesting that their over-representation is not simply the
result of amplification of spacers that are randomly acquired at the early stage of
infection. There are three main possible sources of selective pressure on spacers. One is
a bias in acquisition that may arise either when some protospacers are easier to acquire
by the CRISPR proteins than others [13], or when some protospacers are more
conserved in the viral population, and thus more abundant and more likely to be
acquired. Another possible source of selective pressure is that some spacers might be
more effective than others at clearing viral infections and so provide a selective
advantage for the host [4,10]. Finally, the acquisition of some spacers might be “primed”
by the presence of other spacers in the CRISPR locus [6, 11,14,15].
We construct a population dynamical model for bacteria that use CRISPR-based
immunity to defend against phage. Our model predicts that even when dilution is
negligible, wild-type and spacer-enhanced bacteria can co-exist with phage, provided
there is spacer loss. Previous Lotka-Volterra-like ecological models have demonstrated a
mechanism for coexistence between three species with bounded populations, but, unlike
the scenario we describe, they required dilution and significant differences in the growth
rates of the two prey species [16]. To understand the factors that affect spacer diversity,
we compare two scenarios: (a) different spacers are acquired at different rates; (b)
different spacers provide different advantages, e.g., in growth rate or survival rate, to
the host. We derive analytical results for the spacer distribution that is reached at late
times, and show that the spacer-effectiveness model favors a peaked distribution of
spacers while the spacer-acquisition model favors a more diverse distribution. Higher
rates of spacer acquisition also lead to higher diversity. We expect that greater spacer
diversity will be important for defending against a mutating phage landscape, while a
peaked spacer distribution will confer stronger immunity against a specific threat. Our
model predicts that bacteria can negotiate this tradeoff by controlling the overall rate at
which spacers are acquired, i.e., by modifying the expression of the Cas proteins,
necessary for acquisition [6].
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Model
We consider bacteria that start with a CRISPR cassette containing no spacers, a
scenario that has been proven functional in vivo [17]. We focus on the early dynamics of
the bacterial population after being infected with phage in which each bacterial cell
acquires at most one spacer. Experiments suggest that this scenario may be appropriate
for bacteria-phage interactions lasting about a day, which allows most of the bacterial
population to become immune to the infecting phage, but is not enough time for viral
escapers that can avoid the bacterial defenses to become abundant [12,18]. In the
absence of escapers, the acquisition of new spacers against the same virus is slow [14],
extending the duration for which our single spacer approximation is valid. As time goes
by, the virus will mutate and the bacteria need to acquire new spacers to keep up with
the mutants; we leave the study of this co-evolution to future work, and focus here on
the early dynamics of spacer acquisition.
Even if each bacterial cell only has time to acquire at most one spacer, the
population as a whole will contain a diverse spacer repertoire [12,19,20]. Here we
propose a model of bacteria-phage dynamics to understand the distribution of spacers in
the population. As a warmup, we first study the case where the virus contains only a
single protospacer, then we generalize the model to the case of many protospacers where
acquisition probability and effectiveness can depend on the type.
One spacer type
To set the stage, we will first introduce the dynamics of a model where viruses present a
single protospacer. In this case, all immune bacteria have the same spacer. We will
assume logistic growth of the bacteria [21]. The relevant processes are sketched in Fig. 2
and, assuming a well-mixed population, can be translated into a set of ordinary
differential equations:
n˙0 = f0
(
1− n
K
)
n0 + κn1 − gvn0 ,
n˙1 = f1
(
1− n
K
)
n1 − κn1 − ηgvn1 + αµI0 ,
I˙0 = gvn0 − µI0 ,
I˙1 = ηgvn1 − µI1 ,
v˙ = b (1− α)µI0 + bµI1 − gv(n0 + n1) . (1)
Here the dot represents the derivative with respect to time, n0 is the number of “wild
type” bacteria that do not contain any spacers, n1 is the number of “spacer enhanced”
bacteria that have acquired the spacer, I0 is the number of wild-type infected bacteria,
and I1 is the number of spacer enhanced but infected bacteria (which is possible
because spacers do not provide perfect immunity). The sizes of the bacterial and phage
populations are
n = n0 + n1 + I0 + I1
and v respectively.
The first term in the first two equations in (1) describes logistic growth of the
bacteria with maximum growth rates fi and a carrying capacity K. These equations
allow for the possibility that spacer enhanced bacteria may grow at a different rate than
the wild type because of possible spacer toxicity due to auto-immune interactions or due
to increased metabolic rate arising from expression of CRISPR (Cas) proteins and/or
CRISPR RNA (crRNA). However, there is evidence [12,22] that these growth rate
differences are small so that r = f1/f0 ≈ 1. We also assume that spacers can be lost at
a rate κ (second term in the first and second equations) allowing bacteria to revert to
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Fig 1. Schematic of the CRISPR acquisition and interference mechanism. PAM stands
for protospacer adjacent motif, a short sequence necessary for protospacer recognition
by the Cas proteins.
wild type [22–24]. Bacteria become infected with different rates depending on their
type—wild type are always infected if they encounter phage, but spacer enhanced
bacteria may evade infection. Taking g to be the encounter rate, wild type are infected
at a rate g while spacer enhanced bacteria are infected at a rate ηg where η < 1 (third
terms of the first and second equations). We can think of η as a “failure probability” of
the spacer as a defense mechanism, or alternatively, of 1− η as a measure of the
“effectiveness” of the spacer against infections. Finally, some infected wild-type bacteria
survive and acquire a spacer with probability α (last term in the second equation). We
can imagine that this acquisition occurs in the course of an infection that is unsuccessful
because the phage is ineffective or because of innate immune mechanisms, while
nevertheless allowing the bacterial cell access to genetic material of the phage. We are
neglecting the possibility that spacers might also be acquired via horizontal gene
transfer without an infection.
The dynamics of the infected bacteria is given in the third and fourth equations in
(1). We assume that infected bacteria do not divide. So the number of infected bacteria
grows only because of new infections (first terms in the equations), and declines due to
lysis or successful defense followed by acquisition of spacers (second term). The lysis
rate µ depends on properties of the phage including the burst factor b (i.e., the number
of viral particles produced before lysis). More specifically, there is a delay between
infection and lysis because it takes some time for the virus to reproduce. We are
approximating this delay with a stochastic process following an exponential distribution
with timescale 1/µ [25, 26].
Finally, the last equation describes the dynamics of free phage. The first two terms
model viral replication. Phage that duplicate in infected bacteria produce b new copies
after cell lysis. The first term describes this process in infected wild type bacteria that
do not acquire a spacer and become immune. The second term describes the lysis of
bacteria that were infected despite having a spacer. We could imagine that a small
number of spacer enhanced bacteria that become infected then become resistant again,
perhaps by acquiring a second spacer. We neglect this because the effect is small for two
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Fig 2. Model of bacteria and phage dynamics. Bacteria are either wild type or spacer
enhanced, grow at different rates f0 and f1 and can be infected by phage with rates g
and ηg. Spacers can be acquired during infection with a probability α and spacers are
lost at a rate κ.
reasons—acquisition is rare, α 1, and because we assume that the spacer is effective,
η  1, such that I1 is small. The approximation η  1 is supported by experimental
evidence that shows that a single spacer seems often sufficient to provide almost perfect
immunity [4].
For simplicity, our model does not include the effects of natural decay of phage and
bacteria as these happen on timescales that are relatively long compared to the
dynamics that we are studying. Likewise, we did not consider the effects of dilution
which can happen either in controlled experimental settings like chemostats, or in some
kinds of open environments. In S1 file we show that dilution and natural decay of
typical magnitudes do not affect the qualitative character of our results.
We can also write an equation for the total number of bacteria n:
n˙ = f0(n0 + rn1)
(
1− n
K
)
− µ(1− α)I0 − µI1 , (2)
where we used the notation r = f1/f0. The total number of bacteria is a useful quantity,
since optical density measurements can assess it in real time.
Multiple spacer types
Typically the genome of a given bacteriophage contains several protospacers as
indicated by the occurrence of multiple PAMs. Even though in the short term each
bacterial cell can acquire only one spacer type, at the level of the whole population
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many types of spacers will be acquired, corresponding to the different viral protospacers.
Experiments show that the frequencies with which different spacers occur in the
population are highly non-uniform, with a few spacer types dominating [12]. This could
happen either because some spacers are easier to acquire than others, or because they
are more effective at defending against the phage.
We can generalize the population dynamics in (1) to the more general case of N
spacer types. Following experimental evidence [22] we assume that all bacteria, with or
without spacers, grow at similar rates (f)—the effect of having different growth rates is
analyzed in S1 file. We take spacer i to have acquisition probability αi and failure
probability ηi. As before, we can alternatively think of 1− ηi as the effectiveness of the
spacer against infection. The dynamical equations describing the bacterial and viral
populations become
n˙0 = f
(
1− n
K
)
n0 + κ
N∑
i=1
ni − gvn0 ,
n˙i = f
(
1− n
K
)
ni − κni − ηigvni + αiµI0 ,
I˙0 = gvn0 − µI0 ,
I˙i = ηigvni − µIi ,
v˙ = b
(
1−
N∑
i=1
αi
)
µI0 + bµ
N∑
i=1
Ii − gv
(
n0 +
N∑
i=1
ni
)
(3)
where ni and Ii are the numbers of healthy and infected bacteria with spacer type i,
and α =
∑N
i=1 αi is the overall probability of wild type bacteria surviving and acquiring
a spacer, since the αi are the probabilities of disjoint events. This implies that α < 1.
The total number of bacteria is governed by the equation
n˙ = f
(
1− n
K
)(
n−
N∑
i=0
Ii
)
− µ(1− α)I0 − µ
N∑
i=1
Ii . (4)
Results
The two models presented in the previous section can be studied numerically and
analytically. We use the single spacer type model to find conditions under which
host–virus coexistence is possible. Such coexistence has been observed in
experiments [18] but has only been explained through the introduction of as yet
unobserved infection associated enzymes that affect spacer enhanced bacteria [18].
Host-virus coexistence has been shown to occur in classic models with serial dilution [16],
where a fraction of the bacterial and viral population is periodically removed from the
system. Here we show additionally that coexistence is possible without dilution
provided bacteria can lose immunity against the virus. We then generalize our results to
the case of many protospacers where we characterize the relative effects of the ease of
acquisition and effectiveness on spacer diversity in the bacterial population.
Extinction versus coexistence with one type of spacer
The numerical solution of the single-spacer population dynamics model is shown in
Fig. 3a and Fig. 3b for different parameter choices; more details can be found in S1 file.
In all cases, the bacterial population grows initially because infected bacteria do not die
instantly. If the viral load is high, most bacteria are quickly infected and growth starts
slowing down since infected bacteria cannot duplicate. After a lag of order 1/µ, where µ
6/17
is the rate at which infected bacteria die, the population declines due to lysis. If the
viral load is low, the division of healthy bacteria dominates the death of infected ones,
until the viral population released by lysis becomes large enough to infect a substantial
fraction of the bacteria.
Some infected bacteria acquire the spacer that confers partial immunity from the
phage. During every encounter between a bacterial cell and a virus, there is a
probability η that the spacer will be ineffective. Thus the expected increase in the
number of viral particles following an encounter is bη − 1 where b is the viral burst size
following lysis of an infected cell. If η > 1/b, the viral growth cannot be stopped by
CRISPR immunity and the bacteria are eventually overwhelmed by the infection. Thus
whenever the virus has a high burst factor, only a population with an almost perfect
spacer (the failure probability η < 1/b 1) is able to survive infection.
The viral concentration has a more complex dynamics—it typically reaches a
maximum, then falls due to CRISPR interference, and starts oscillating at a lower value
(Fig. 3b). The initial rise of the viral population occurs because of successful infections
of the wild-type bacteria. But then, the bacteria which have acquired effective spacers
grow exponentially fast, virtually unaffected by the presence of the virus. Since the
virus is adsorbed by immune bacteria, but are cleaved by CRISPR and cannot duplicate,
the viral population declines exponentially. However, as the population of
spacer-enhanced bacteria rises, so does the population of wild type, because of the
constant rate of spacer loss. This starts a new growth period for the virus, leading to
the oscillations seen in simulations. When spacer effectiveness is low, the virus can still
have some success infecting spacer-enhanced bacteria, and the oscillations are damped.
It would be interesting to test whether large oscillations in the viral concentration can
be seen in experiments to see if these are compatible with measured estimates of the
rate of spacer loss κ in the context of our model [22,27].
Varying the growth rate of the bacteria with CRISPR relative to the wild type has a
strong effect on the length of the initial lysis phase and the delay before exponential
decay of the viral population sets in. In contrast, a lower effectiveness of the CRISPR
spacer (i.e., larger failure probability η; green line in Fig. 3b) leads to a higher minimum
value for the viral population and weaker oscillations. This could potentially be used to
disentangle the effects of growth rate and CRISPR interference on the dynamics.
After a transient period, the dynamics will settle into a stationary state. The
transient is shorter if the spacer enhanced growth rate f1 is high, or if the failure
probability of the spacer η is low (Fig. 3, panel a and b). Depending on the choice of
initial values and the parameters, there are different steady states. If spacers are never
lost (κ = 0), we found numerically that a stable solution occurs when viruses go extinct
and infections cease (v = 0, I0,1 = 0). In this case, the total number of bacteria becomes
stationary by reaching capacity (n = K), which can only happen when the spacer is
sufficiently effective (η < 1/b). Otherwise bacteria go extinct first (n = 0) and then the
virus persists stably.
A more interesting scenario occurs when spacers can be lost (κ 6= 0). In this case
coexistence of bacteria and virus (n > 0 and v > 0) becomes possible (see SI for an
analytic derivation). In this case, the bacteria cannot reach full capacity at steady
state—we write n = K(1−F), where the factor
F = 1− n
K
(5)
represents the fraction of unused capacity. The general expression for F is given in the
SI, and simplifies when the wild type and spacer enhanced bacteria have the same
growth rate (f1 = f0) to
F = κ
f0
b(1− α)− 1
(b− 1)(1− bη) . (6)
7/17
Fig 3. Model of bacteria with a single spacer in the presence of lytic phage. (Panel a)
shows the dynamics of the bacterial concentration in units of the carrying capacity
K = 105 and (Panel b) shows the dynamics of the phage population. In both panels,
time is shown in units of the inverse growth rate of wild type bacteria (1/f0) on a
logarithmic scale. Parameters are chosen to illustrate the coexistence phase and damped
oscillations in the viral population: the acquisition probability is α = 10−4, the burst
size upon lysis is b = 100. All rates are measured in units of the wild type growth rate
f0: the adsorption rate is g/f0 = 10
−5, the lysis rate of infected bacteria is µ/f0 = 1,
and the spacer loss rate is κ/f0 = 2× 10−3. The spacer failure probability (η) and
growth rate ratio r = f1/f0 are as shown in the legend. The initial bacterial population
was all wild type, with a size n(0) = 1000, while the initial viral population was
v(0) = 10 000. The bacterial population has a bottleneck after lysis of the bacteria
infected by the initial injection of phage, and then recovers due to CRISPR immunity.
Accordingly, the viral population reaches a peak when the first bacteria burst, and
drops after immunity is acquired. A higher failure probability η allows a higher steady
state phage population, but oscillations can arise because bacteria can lose spacers (see
also S1 file). (Panel c) shows the fraction of unused capacity at steady state (Eq. (6)) as
a function of the product of failure probability and burst size (ηb) for a variety of
acquisition probabilities (α). In the plots, the burst size upon lysis is b = 100, the
growth rate ratio is f1/f0 = 1, and the spacer loss rate is κ/f0 = 10
−2. We see that the
fraction of unused capacity diverges as the failure probability approaches the critical
value ηc ≈ 1/b (Eq. (7)) where CRISPR immunity becomes ineffective. The fraction of
unused capacity decreases linearly with the acquisition probability following Eq. (6).
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Fig. 3c shows the dependence of F on the failure probability of the spacer (η) multiplied
by the burst factor (b). We see that even if the spacer is perfect (η = 0) the steady state
bacterial population is less than capacity (F > 0). These equations are valid when
F < 1—this is only possible if the spacer failure probability (η) is smaller than a critical
value (ηc), where
ηc =
1
b
(
1− κ
f0
b(1− α)− 1
b− 1
)
+O
(
r − 1
b2
)
, (7)
where as before r = f1/f0. This coexistence phase has been found in experiments [18]
where the bacterial population reaches a maximum that is “phage” limited like in our
model.
In the coexistence phase, the wild type persists at steady state, as observed in
experiments [18]. In our model, the ratio of spacer-enhanced and wild-type bacteria is
n1
n0
=
b(1− α)− 1
1− bη . (8)
This ratio does not depend on the growth rates of the two types of bacteria (f1 vs. f0).
So, given knowledge of the burst size b upon lysis, the population ratio in Eq. (8) gives
a constraint relating the spacer acquisition probability α and the spacer failure
probability η. Thus, in an experiment where phage are introduced in a well mixed
population of wild type and spacer enhanced bacteria, Eq. (8) presents a way of
measuring the effectiveness of a spacer, provided the machinery for acquisition of
additional spacers is disabled (α = 0) (e.g., by removing specific Cas proteins) [4, 28].
Plugging the effectiveness values measured in this way into our model could then be
used to predict the outcome of viral infections in bacterial colonies where individuals
have different spacers, or have the possibility of acquiring CRISPR immunity.
The lysis timescale 1/µ for infected cells affects the duration of the transient
behavior of the population, as described above. The longer this timescale, the longer it
takes to reach the steady state. However, the actual size of the steady state population
is not dependent on µ because this parameter controls how long an infected cell persists,
but not how likely it is to survive. This is analyzed in more detail in S1 file.
In previous models, coexistence of bacteria and phage was achieved by hypothesizing
the existence of a product of phage replication that specifically affects spacer-enhanced
bacteria compared to wild type [18]. Here we showed that coexistence is obtained more
simply if bacteria can lose spacers, a phenomenon that has been observed
experimentally [22,23]. More specifically, in our model coexistence requires two
conditions: (1) spacer loss (κ > 0), and (2) the failure probability of spacers is smaller
than a critical value (η < ηc). Our model also reproduces an effect observed by [18],
namely that the steady state bacterial population is reduced by the presence of virus.
While this may seem intuitive, previous population dynamics models have not
reproduced this finding, which depends critically in our model on the rate of spacer loss.
Effectiveness versus acquisition from multiple spacers
We can now proceed to analyze the case where multiple protospacers are presented. As
before, when we analyze the multiple spacer model, the most interesting case is when
the virus and bacteria can co-exist. The bacteria do not generally fill their capacity
when this happens. The fraction of unused capacity (F = 1− n/K) can be
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characterized using the average failure probability (η¯):
F = κ
f
b(1− α)− 1
(1− bη¯)(b− 1) ,
η¯ =
∑N
i=1 ηini∑N
i=1 ni
.
(9)
Bacteria and phage co-exist if F < 1 so that bη¯ < 1− κ(b(1−α)−1)f(b−1) . This is an implicit
expression because η¯ itself depends on the distribution of bacteria with different spacers.
The coexistence solution can be computed analytically
gv = bfF ,
ni
n0
= αi
bfF
κ− fF(1− ηib) ,∑N
i=1 ni
n0
=
b(1− α)− 1
1− bη¯ .
(10)
We see that the spacer distribution depends on the acquisition and failure probabilities
(αi and ηi). As discussed in the single spacer case, the third equation gives a way to
measure the average failure probability (η¯) of spacers by turning off the acquisition
machinery after a diverse population of spacers is acquired [4, 28]. (This remains true
even if the spacer also affects the growth rate—see S1 file). Given knowledge of the
spacer failure probabilities (ηi) from single spacer experiments, we can also obtain the
acquisition probabilities (αi) by measuring the ratio of spacer enhanced to wild type
bacteria (ni/n0) and using the second equation in (10).
The second equation in (10) also allows us to make qualitative predictions about
mechanisms affecting the steady state spacer distribution. First, the steady state
abundance of each spacer type is proportional to its probability of acquisition (αi). This
implies that, if all else is kept fixed, a large difference in abundance can only come from
a large difference in acquisition probability (see Fig. 4a).
In contrast, the dependence on the failure probability (ηi) appears in the
denominator, so that large variations in abundance can follow from even modest
differences in effectiveness (Fig. 4b). When spacers differ in both acquisition and failure
probability, the shape of the distribution is controlled mostly by the differences in
effectiveness, with acquisition probability playing a secondary role (Fig. 4c). This
suggests that the distribution of spacers observed in experiments, with a few spacer
types being much more abundant than the others [12], is likely indicative of differences
in the effectiveness of these spacers, rather than in their ease of acquisition. The
distribution of spacers as a function of ease of acquisition and effectiveness is shown for
a larger number of spacers in S1 File (Fig. D), with the same qualitative findings.
Our model also predicts that the overall acquisition probability (α) is important for
controlling the shape of the spacer distribution. Large acquisition probabilities tend to
flatten the distribution, leading to highly diverse bacterial populations, while smaller
acquisition probabilities allow the most effective spacers to take over (Fig. 4b). This
raises the possibility that the overall spacer acquisition probability of bacteria could be
under evolutionary selection pressure as a means of trading off the benefits conferred by
diversity in dealing with an open environment against the benefits of specificity in
combatting immediate threats. This idea could be tested in directed evolution
experiments where bacteria are grown in artificial environments with less or more
variability in the phage population.
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Fig 4. The distribution of bacteria with 20 spacer types. In these simulations, 100
phage are released upon lysis (burst size b = 100) and the carrying capacity for bacteria
is K = 105. All rates are measured in units of the bacterial growth rate f : the lysis rate
is µ/f = 1, the phage adsorption rate is g/f = 10−4, the spacer loss rate is κ/f = 10−2.
(Panel a) Distribution of spacers as a function of acquisition probability αi given a
constant failure probability ηi = η. Eq. (10) shows that the abundance depends linearly
on the acquisition probability: ni/n ∝ αi/α. Horizontal lines give the reference
population fraction of all spacers if they all have the same acquisition probability with
the indicated failure probability η. (Panel b) Distribution of bacteria with different
spacers as a function of failure probability ηi given a constant acquisition probability
αi = α. For small α, the distribution is highly peaked around the best spacer while for
large α it becomes more uniform. (Panel c) The distribution of spacers when both the
acquisition probability αi and the failure probability ηi vary. The three curves have the
same overall acquisition rate α =
∑
i αi = .0972. The color of the dots indicates the
acquisition probability and the x-axis indicates the failure probability of each spacer.
When the acquisition probability is constant (green curve i.e. αi = α/20) the
population fraction of a spacer is determined by its failure probability. If the acquisition
probability is anti-correlated with the failure probability (blue curve), effective spacers
are also more likely to be acquired and this skews the distribution of spacers even
further. If the acquisition probability is positively correlated with the failure probability
(red curve), more effective spacers are less likely to be acquired. Despite this we see that
the most effective spacer still dominates in the population.
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Discussion
The CRISPR mechanism in bacteria is an exciting emerging arena for the study of the
dynamics of adaptive immunity. Recent theoretical work has explored the co-evolution
of bacteria and phage [18,29,30]. For example, Levin et al. [18] modeled several
iterations of an evolutionary arms race in which bacteria become immune to phage by
acquiring spacers, and the viral population escapes by mutation. Han et al. [29] studied
coevolution in a population dynamics model in which there are several viral strains,
each presenting a single protospacer modeled by a short bit string. Childs et al. [30] also
used a population dynamics model to study the long-term co-evolution of bacteria and
phage. In their model, bacteria can have multiple spacers and viruses can have multiple
protospacers, and undergo mutations.
Our goal has been to model the effect of different properties of the spacers, such as
their ease of acquisition and effectiveness, on their abundance in a setting where there is
only enough time to acquire a single spacer. The reason for the latter restriction is that
it leads to a more easily interpretable experimental setting. Our goal is not to study
long-term bacteria-virus co-evolution, but rather to build a model of the early dynamics
of CRISPR immunity that will allow experimentalists to extract key dynamical
parameters from their data. An advantage of our model is that it allows study of
regimes with a large number of spacer types. We aimed for a model with the minimal
interactions that could explain existing observations, such as an over-abundance of a
small number of spacers compared to the rest and the coexistence of phage and
bacteria [12,18,20]. We are specifically interested in the possibility that encounters with
a single phage could lead to the acquisition of diverse spacers [19], a phenomenon that
could not be explained by the model of Han et al. [29]. Likewise, Levin et al. [18] did
not explicitly model the spacer types and hence could not address their diversity.
Furthermore, their model captured coexistence by postulating an as-yet-undetected lysis
product from wild type bacteria that harms spacer enhanced ones. By contrast, we
showed above that coexistence, in absence of any other mechanisms of immunity, can be
obtained simply by including spacer loss, which has been experimentally
observed [22,27,31].
Coexistence was also addressed by Haerter el al. [32] and Iranzo et al. [24]. Haerter
et al. exploit spatial heterogeneity, while our model shows that coexistence can also
occur in well-mixed populations. Coexistence in [24] occurs due to innate immunity for
wild type bacteria. In the latter model, the CRISPR mechanism is taken to incur a cost
to the bacteria, and thus loss of the CRISPR locus can occur as a consequence of
competition between CRISPR and other forms of immunity, but is not an essential
ingredient for coexistence. Their study also focused on longer timescales compared to
our work. Childs et al. [30] discuss the possibility of coexistence, but only in the context
of homogeneous bacterial populations, that are either all immune or all wild type. We
show that coexistence of both immune and wild type bacteria with phage is possible
given a nonzero rate of spacer loss. Finally, Weinberger et al. [33] used a population
genetic model in which the sizes of the bacterial and phage populations are fixed, thus
precluding study of the conditions required for coexistence. The model also did not
consider potential differences in the efficacy of spacers.
Coexistence can also be obtained by placing the bacteria and phage in a chemostat
or subjecting them to serial dilutions [16]. While in some ways this may be a better
approximation for natural environments, in this work we focus on experimental
conditions in which the interaction takes place in a closed environment. We predict that
when dilution is negligible, spacer loss is necessary for the existence of a phase where
wild-type bacteria, spacer-enhanced bacteria, and phage co-exist. When there is
dilution, coexistence can occur without spacer loss [16], but we show in S1 file that this
requires a difference in the growth rates of wild-type and spacer-enhanced bacteria.
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This difference is known to be small in general [12,22], and hence the dilution
mechanism for coexistence will lead to small viral populations at steady state which will
be at risk of extinction due to stochastic variation. By contrast, coexistence through
spacer loss can support robust steady state viral populations.
We have also addressed factors that influence the spacer distribution across the
bacterial population. This issue was also studied in He et al. [34] and Han et al. [29],
but they focused on the way in which diversity depends on position within the CRISPR
locus as opposed to the properties of spacers that influence their relative abundance.
Childs et al. [19,30] were also interested in spacer diversity, but assumed that all spacers
have similar acquisition probabilities and effectiveness, while we have sought precisely to
understand how differences in these parameters affect diversity.
Our model makes several predictions that can be subjected to experimental test.
First, spacer loss [22,27,31] is a very simple mechanism that allows for coexistence of
bacteria and phage. In particular, spacer loss allows coexistence even in the absence of
dilution, and permits robust steady state viral populations even if the growth rates of
wild-type and spacer-enhanced bacteria are similar. Direct measurements of the rates of
spacer loss may be possible, and would furnish an immediate test of our model.
Alternatively, our model provides a framework for an indirect measurement of the
spacer loss rate. Specifically, this rate is proportional to the viral population and the
fraction of unused capacity at steady state. When the probability of spacer loss is small,
our formalism predicts a correspondingly small average viral population.
Of course, the population in any given experiment experiences fluctuations which
could lead to extinction. An interesting avenue for future work is to include such
stochasticity, which would then predict the typical time-scale for viral extinction
corresponding to a given probability of spacer loss. This time-scale can be compared
with experimental observations [35]. A stochastic model of this dynamics was used by
Iranzo et al. [24], but did not consider differences in spacer effectiveness. In order to
check whether the result from a stochastic scenario would be different from what we
found, we checked the stability of the deterministic solution with respect to initial
conditions. The system is able to equilibrate in a reasonable time-scale suggesting that
the deterministic solution is stable. This is an indication of robustness against
stochastic fluctuations.
The effectiveness parameters in our model could be extracted in experiments where
bacteria are engineered to have specific spacers [36] and acquisition is disabled [4,28]. In
principle the acquisition parameters could be measured by freezing bacterial populations
soon after an infection, although initial conditions would require careful control. Once
these parameters are measured, they can be plugged back into the full set of equations
to make predictions for the CRISPR dynamics even in the case when acquisition is
enabled. A comparison between the measured and predicted dynamics in the presence
of CRISPR acquisition would constitute a test of our model. Alternatively, our model
could be fit to measured dynamics to extract the parameters and then tested by
comparing with the steady state.
When multiple protospacers are available, we showed that the acquisition probability
linearly affects the steady state spacer distribution, while the proportion of more
effective spacers is magnified by the dynamics. Thus, a highly peaked spacer
distribution as seen in some studies [12] is more likely to occur because of differences in
effectiveness if protospacers are acquired with roughly equal probabilities. In fact, it
does seem that some genomic sequences are acquired more frequently than others [6, 13].
While the mechanism for this enhancement has not been fully clarified, one possibility is
that the more commonly acquired sequences are simply those that are less prone to
mutation in the viral genome. This could be tested by sequencing the virus together
with the CRISPR-cassettes in a co-evolving population of bacteria and phage. This
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mechanism for enhancing acquisition probability of some spacers is readily incorporated
in our model.
Various extensions of our model are possible. For example, in describing longer
timescale experiments we can include the fact that CRISPR cassettes can contain many
spacers [34]. Furthermore, we could include the possibility of “priming” where the
presence of some spacers increases the probability of acquiring others [6]. Such an effect
would introduce correlations between different spacer populations ni and nj that can be
tested experimentally.
Our model showed that high acquisition probabilities will lead to greater diversity in
the spacer distribution, while strong selection will tend to homogenize the population of
spacers in favor of the most effective one for the current threat. This suggests that
bacteria should adapt the overall spacer acquisition probability to the amount of viral
diversity in their environment, perhaps by transcriptional regulation of the cas genes.
Given an appropriate fitness function and viral landscape our modeling framework
could be used to predict the optimal acquisition probability.
Supporting Information
S1 File. Supporting Information.
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I. MATERIALS AND METHODS
We numerically integrated our population dynamics equations using custom code written in C. The order
of magnitude of the burst size b, carrying capacity K and growth rate f were taken from [1], the spacer
loss rate κ was estimated from [2], and the spacer failure probability η and acquisition probability α were
variables that we scanned over. We took the death rate µ of infected bacteria to be comparable to the growth
rate f . To estimate the order of magnitude of the phage adsorption rate g we used a simple argument based
on diffusion. Because of the large difference in size, we approximate phage particles with points and focus
on a single bacterial cell, modeled as a perfectly absorbing sphere of radius R. Fick’s second law, c˙ = D∆c,
can be used to calculate the concentration profile of phage around the bacteria at stationarity, leading to
c(r) = cp
(
1− Rr
)
, where cp is the concentration of phage far away from bacteria. Fick’s first law then gives
us the flux at the sphere, whose integral gives the rate at which phage are absorbed, 4piDcpR, where D is
the diffusion coefficient. Using Einstein’s relation D = kBT6piηrv to estimate the diffusion coefficient (with η the
dynamic viscosity of the medium and rv the size of the virus), we get that an estimate for g is
g =
2
3V
kbT
η
R
rv
, (1)
where V is the experimental volume, which only appears here because we defined g in terms of particle
numbers instead of concentrations. Using V ∼ 1µL, η = 8 × 10−4 Pa · s (for water at 30◦), T = 300 K,
R ∼ 1µm, rv ∼ 0.1µm, we get g ∼ 10−4 hour−1 . This is very close to experimental values observed in in
vitro experiments of bacteria and phage [3].
II. DETAILED DYNAMICS AND STEADY STATE WITH ONE TYPE OF SPACER
A. Transient behavior
In addition to the numerical studies presented in the main text, some aspects of the dynamics of our model
can be described analytically. This allows us to get further insights into general features of the solutions and
how these features depend on the parameters.
Let us analyze the initial trend in the bacterial population in the single protospacer model (eq. [1] in the
3main text):
n˙0 = f0
(
1− n
K
)
n0 + κn1 − gvn0 ,
n˙1 = f1
(
1− n
K
)
n1 − κn1 − ηgvn1 + αµI0 ,
I˙0 = gvn0 − µI0 ,
I˙1 = ηgvn1 − µI1 ,
v˙ = b (1− α)µI0 + bµI1 − gv(n0 + n1) .
(2)
At the time of inoculation, the population is entirely wild type, so n1(0) = 0, and there are no infected
bacteria, I0(0) = 0, I1(0) = 0. The total bacterial population is n(0) ≡ n0(0) < K. The dynamics of n(t)
are governed by eq. [2] from the main text,
n˙ = f0(n0 + rn1)
(
1− n
K
)
− µ(1− α)I0 − µI1 , (3)
which implies that in this case n˙(0) > 0, i.e., the bacteria always start off with growth. This is a result
of the latency between viral infection and death. However, we expect this growth to be short lived: after
a time of order µ−1, the infected cells should start dying and the bacterial population should go down. It
turns out that growth can sometimes last much longer than that, as shown below.
Suppose we have t 1/µ and, for simplicity, assume n0(0) K; from the system of equations (2) we get
n0 = n0(0) +
[
f0 − gv(0)
]
n0(0) t+O(t2) ,
I0 = gv(0)n0(0) t+O(t2) .
(4)
Similarly n1 = O(t2) and I1 = O(t2), implying that
n˙ = f0n0(0)
{
1− t
[
gv(0)
(
1 +
µ(1− α)
f0
)
− f0
]}
+O(t2) . (5)
If gv(0) > f0 then growth ends in a time
tp =
1
gv(0)
(
1 + µ(1−α)f0
)
− f0
<
f0
µ(1− α)gv(0)
<
1
µ(1− α) ≈
1
µ
,
(6)
assuming that the acquisition probability α is small. Conversely, if
gv(0) <
f0
1 + µ(1− α)/f0 , (7)
the initial growth of the wild type bacteria continues past the initial latency time t = 1/µ. This prediction of
the model can be tested via optical density measurements. Of course, past this time, the approximations we
made above no longer hold; eventually the wild type population will decline, being overtaken by the virus,
and the bacteria will go through a bottleneck; see Fig. 3 of the main text. Recovery from this bottleneck is
due to CRISPR spacer acquisition.
B. Steady state solutions and stability analysis
a. Coexistence solution: v 6= 0 and n 6= 0. The steady state solutions for the system in eq. (2) are
obtained by setting all the derivatives to zero. Solving the equations for the number of infected bacteria and
4plugging these into the equation for the viral dynamics, we get
I0 =
g
µ
vn0 ,
I1 =
gη
µ
vn1 ,
n1 =
b(1− α)− 1
1− bη n0 ,
(8)
where we assumed v 6= 0.
Since Ii, ni, and v are population numbers, they must be non-negative. From eq. (8) above, this requires
that bη < 1 and bα < b − 1 (in principle the opposite conditions could also hold, bη > 1 and bα > b − 1,
implying α > (b−1)/b. However, in realistic conditions, b is large (of order 100 or 1000), and so (b−1)/b ≈ 1,
while α is typically much smaller than 1). If these conditions are not met, the co-existence solution is not
feasible, and we get either ni = Ii = 0 or v = 0.
The remaining steady state values can be obtained after some tedious but straightforward algebra:
n = K(1−Fr) ,
Fr = κ
f0
b(1− α)− 1
(1− bη)
(
b− 1 + (r − 1)b(1− α)− 1
1− α− η
) ,
gv = f0Fr + κ b(1− α)− 1
1− bη ,
n0
n
=
µ(1− bη)
bµ(1− α− η) +
(
f0Fr + κ
b(1− α)− 1
1− bη
)
(1− η − ηbα)
,
n1
n
=
µ(b(1− α)− 1)
bµ(1− α− η) +
(
f0Fr + κ
b(1− α)− 1
1− bη
)
(1− η − ηbα)
,
(9)
where we see that the virus concentration at steady state is proportional to the rate of spacer loss (κ). Here
the notation Fr is used to emphasize the fact that we allow for different growth rates for wild type and
spacer enhanced bacteria.
Compared to the expression from eq. [3] in the main text, the fraction of unused capacity (F) changes
when the wild type and spacer enhanced growth rates are unequal. The magnitude of the change obeys
Fr
F =
1
1 + γ
b(1− α)− 1
(b− 1)(1− α− η)
= 1− γ b(1− α)− 1
(b− 1)(1− α− η) +O(γ
2) , (10)
where γ = r − 1.
The positivity of n0 and n1 also implies that Fr < 1. This translates into a more stringent condition on
the failure probability of the spacer (η). For bacteria to be able to resist infection and for the co-existence
solution to be feasible, we need η < ηc, where the critical failure probability is
ηc =
1
b
(
1− κ
f0
b(1− α)− 1
b− 1
)
+ γ
κ
f0
b(1− α)− 1
(b− 1)(b− 1 + κ/f0) − γ
2 κ
f0
b
(
b(1− α)− 1)
(b− 1 + κ/f0)3 +O(γ
3) . (11)
This gives the next couple of terms in the expansion in eq. [4] in the main text. We write this as an expansion
in γ = r − 1 because experiments suggest that differences between the growth rates of wild type and spacer
enhanced bacteria are small.
Another interesting limit to consider is when the burst size b is very large, which is the case for typical
viruses. When b→∞, the product between the burst size and the critical failure probability simplifies to
bηc = 1− κ(1− α)
f1
+O(b−1) . (12)
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Fig A. Time-dependence of the population of wild type bacteria, both growing (n0) and infected (I0), the fraction
of carrying capacity occupied by bacteria (n/K), and the viral population (v) for various choices of acquisition
probability (α; left panel) and rate of spacer loss (κ; right panel). Both axes are on a log-scale because the dynamic
range varies significantly between the early and late periods. Other parameters are chosen similar to the main text:
the growth rates of spacer enhanced and wild type bacteria are equal (r = 1), the phage adsorption rate is given by
g/f0 = 10
−5, the death rate of infected bacteria is given by µ/f0 = 1, the burst factor is b = 100, and the spacer
failure probability η = 0. The initial population is all wild type n = n0 = 1000 and maximum capacity K = 10
5, and
the initial multiplicity of infection (MOI; v/n) is 10 such that v(0) = 104. In the left panel, the rate of spacer loss is
kept fixed at κ/f0 = 0.001. In the right panel, the acquisition probability is kept fixed at α = 0.003. We see that the
oscillations in the wild type bacteria and viral populations are more strongly damped for large spacer loss rates.
This means that, apart from being inversely proportional to the burst factor, the critical failure rate at large
b only depends on the rate of spacer loss (κ), the acquisition probability (α), and the growth rate of the
spacer enhanced bacteria (f1). In particular, it does not depend on the wild type growth rate.
A numerical study shows that when the coexistence solution exists (η < ηc), it is also stable for a wide
range of parameters. Altering the spacer acquisition probability (α), the rate of spacer loss (κ), or the failure
probability (η) in a wide range does not preclude the coexistence state, although it can lead to significant
changes in the population dynamics (see Fig. A and Fig. B). Interestingly, the dynamics of the total number
of bacteria (n) is almost insensitive to the rate of spacer loss (κ). The viral population, and therefore also
the population of infected bacteria, are much more strongly affected by changes in the rate of spacer loss.
Frequent loss of spacers leads to a stronger damping and shorter period for the oscillations in the viral
population, while less frequent loss greatly enhances the amplitude of these oscillations.
The ability to acquire spacers has a large effect on the early dynamics of the bacterial population, while
not greatly affecting the viral dynamics. Lower acquisition probabilities lead to a tighter bottleneck for the
bacteria, as they require a longer time to gain the CRISPR immunity that they need to fight viral infection.
The spacer failure probability (η) does not affect the total bacterial population too much, but has a large
effect on the steady state population of phage and wild type bacteria, as well as on the transient dynamics
leading to the steady state. More effective spacers lead to larger numbers of wild type bacteria and fewer
viruses, shorter transients, and more oscillatory dynamics. In contrast, bacteria with less effective spacers
(larger η) can take a long time to reach steady state, don’t seem to exhibit oscillations, and lead to fewer
wild type bacteria and more viruses.
When stochastic effects are taken into consideration, random fluctuations could lead to extinction of either
bacteria or phage when these go through bottlenecks. Thus, smaller acquisition probabilities lead to higher
chances of bacterial extinction, while smaller rates of spacer loss would be dangerous for the phage’s survival.
Very effective spacers also increase the oscillations in the viral dynamics, while also lowering the steady state
viral population, so they too can contribute to viral extinction.
b. Virus extinction v = 0. When the virus goes extinct (v = 0), the steady state populations of wild
type and spacer enhanced bacteria can depend on the initial conditions. We can gain some intuition into
this case by considering a model in which the virus has already gone extinct; thus, v = 0 and I0 = I1 = 0.
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Fig B. Time-dependence of the population of wild type bacteria, both growing (n0) and infected (I0), the fraction of
carrying capacity occupied by bacteria (n/K), and the viral population (v) for various choices of the spacer failure
probability (η). Both axes have a log scale to better reveal the dynamical range. Other parameters are chosen similar
to the main text: the growth rates of spacer enhanced and wild type bacteria are equal (r = 1), the phage adsorption
rate is given by g/f0 = 10
−5, the death rate of infected bacteria is given by µ/f0 = 1, the burst factor b = 100, the
rate of spacer loss is κ/f0 = 0.002 and acquisition probability α = 0.003. The initial population is all wild type,
n(0) = n0(0) = 10
3 and the initial multiplicity of infection (MOI; v/n) is 10 that means v(0) = 104.
In this case, the system of equations simplifies to
n˙0 = f0
(
1− n
K
)
n0 + κn1 ,
n˙1 = f1
(
1− n
K
)
n1 − κn1 ,
(13)
If we assume that the wild type and spacer enhanced growth rates are equal (f1 = f0), the solution can be
found analytically:
n(t) =
Kn(t0) e
f0(t−t0)
K − n(t0)
(
1− ef0(t−t0)) ,
n1(t)
n(t)
=
n1(t0)
n(t0)
e−κ(t−t0) ,
n0(t)
n(t)
= 1− n1(t)
n(t)
,
(14)
where t0 is the initial time and n(t0) and n1(t0) are the initial total population of bacteria and the initial
population of spacer enhanced bacteria, respectively. In the long term limit the bacterial population reaches
the carrying capacity, n(t) → K. If there is spacer loss (κ 6= 0), the spacer enhanced bacteria eventually
disappear, so the steady state in this case is n0 = n = K, n1 = 0, independently of initial conditions. If there
is no spacer loss (κ = 0), the fraction of bacteria that are spacer enhanced stays constant as the bacteria
grow to capacity.
We can use this result to understand what happens in the more general case when the viral population
starts off non-zero but eventually dies out (v → 0). In this case we need to compute the viral extinction time
t0 = teff such that v(teff) ∼ 0. The arguments above suggest that viral extinction can only happen if there
is no spacer loss – this is because even an exponentially small number of viruses will be able to multiply if
presented with wild-type bacteria. Assuming the spacer loss rate is zero, the fraction of the total bacterial
population that contains spacers will stay approximately constant from the time of viral extinction.
We can also investigate what happens when the spacer enhanced growth rate differs from that of the wild
type, but this requires numerical simulations (Fig. C). Just like in the case when the growth rates are equal,
the population of spacer-enhanced bacteria n1(t) decays exponentially to zero at large times.
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Fig C. Dynamics of the fraction of spacer enhanced bacteria in absence of virus. The plots show the numerical
solution of the system of equations given in (13) when K = 105 and spacer enhanced and wild type growth rates
are different (r = f1/f0 6= 1). The initial values n1(0) = n0(0) = 50, n(0) = 100 and κ = .01. For comparison, we
show the analytical solution reported in eq. (14) for the special case r = 1 (black line). The long-term decay of the
spacer-enhanced population relative to wild type is simply due to spacer loss in the absence of virus. In the inset we
emphasize the exponential decays for longer time scales by using a log scale.
In summary, when bacteria can lose spacers and the failure probability is lower than the critical value
from eq. (11), virus and bacteria co-exist in a steady state after the initial transient dynamics.
III. EXTENSIONS OF THE MODEL
In realistic situations, bacteria and viruses undergo decay even in the absence of any external threats. We
can incorporate this into our model by adding decay terms into the system of equations (2):
n˙0 = f0
(
1− n
K
)
n0 + κn1 − gvn0 − sn0 ,
n˙1 = f1
(
1− n
K
)
n1 − κn1 − ηgvn1 + αµI0 − sn1 ,
I˙0 = gvn0 − (µ+ s)I0 ,
I˙1 = ηgvn1 − (µ+ s)I1 ,
v˙ = b (1− α)µI0 + bµI1 − gv(n0 + n1)− s′v .
(15)
Here s is the decay rate for bacteria, assumed to be the same regardless whether they are infected or not
and whether they are spacer enhanced or wildtype, while s′ is the decay rate for phage.
The formalism above can also be used to model a rather different phenomenon: the dynamics of a mixture
of bacteria and phage in the case where the experimental preparation includes serial dilutions or chemostats.
In these cases, the bacterial culture is either periodically or continuously removed and added to fresh sterile
medium. This leads to a continual renewal of nutrients that allows the bacterial population to keep growing.
If natural decay is negligible compared to dilution, we can set s′ = s in eqs. (15).
To simplify the analysis, we look at two cases: viral decay without bacterial decay, and dilution. The
general case can be treated similarly.
A. Viral decay
We start with the case in which viruses decay at a rate s′, but there is no bacterial decay (s = 0). We
look for steady state solutions for eqs. (15), with the added simplification of ignoring spacer loss, κ = 0.
8We will generally assume that the growth rates of spacer enhanced and wild type bacteria are similar, in
accordance with experiments. We will thus write f1 = f0(1 + γ) and perform an expansion in γ. These
approximations greatly simplify the analytical manipulations without changing the qualitative picture for
moderate variations in parameters, as we checked numerically.
There are three types of steady state solutions: 1) a coexistence scenario where spacer enhanced bacteria,
wild type bacteria, and virus coexist; 2) a monoclonal-bacteria scenario where wild type bacteria go extinct
leaving only spacer enhanced; and 3) an infection-free scenario where viruses go extinct.
1. The coexistence scenario.
The steady state solutions expanded to first order in γ = (f1 − f0)/f0 are
n0 =
s′(1− η)
g(b− 1)(1− α− η) +
s′α(1− bη)
g(b− 1)2(1− α− η)2 γ +O(γ
2) ,
n1 =
−s′α
g(b− 1)(1− α− η) +
s′α
(
b(1− α)− 1)
g(b− 1)2(1− α− η)2 γ +O(γ
2) ,
v =
f0µ(1− α− η)
(
(b− 1)gK − s′)
g
[
(b− 1)gKµ(1− α− η) + f0s′(1− αη − η)
] +O(γ) .
(16)
Typically, acquisition and failure probabilities are not large, so that we can expect α + η < 1. This
implies that when the difference in growth rate, γ, is small, n1 in the solution above is formally negative.
Physically, this means that the coexistence scenario is not feasible in the biologically-plausible region
of parameters.
2. The monoclonal-bacteria scenario.
This scenario is characterized by the absence of wild type
n0 = 0 , n1 =
s′
g(bη − 1) , v =
f1µ
[
gK(bη − 1)− s′]
gη
[
gKµ(bη − 1) + f1s′
] . (17)
This solution exists only when the failure rate is high η > 1/b, because n1 must be positive. This regime
is opposite to the one we considered in the main text, where we showed that the bacterial population
can survive only when the failure probability η is small enough to compensate for the infection bursting
factor, η < 1/b. The non-zero viral decay rate acts in favor of the bacteria, giving them a chance to
survive even when the failure probability is high. If spacers can be lost (i.e. κ 6= 0), then some of
the surviving spacer-enhanced bacteria will revert to wild type, thus maintaining a diverse population.
This confirms from a different perspective that spacer loss plays a key role in establishing coexistence
of the virus with both the spacer-enhanced and the wild-type bacteria.
3. The infection-free scenario.
In this case, the viral infection is completely cleared, and we get
n0 = K − n1 , n1 = K b(1− α)− 1
b(1− α− η) −
s′
bg(1− α− η) , v → 0 . (18)
This is the case where the bacterial population is able to cope with the infection and grows up to
maximum capacity. The main difference with respect to the absence of viral decay rate, s′ = 0, is that
wild type reaches a higher value proportional to the rate s′.
B. The dilution regime
In the case of either serial dilutions or chemostat conditions, if we ignore natural decay for bacteria and
phage, the system dilutes both populations at the same rate, s′ = s. As above, we start by neglecting spacer
loss, κ = 0, and consider conditions in which spacer enhanced and wild type bacteria have almost equal
growth rates, so that we can expand in γ = (f1 − f0)/f0.
9We first consider the dynamics in the limit in which the infected bacteria are killed instantaneously,
µ→∞. In this case, the system of equations simplifies to
n˙0 = f0
(
1− n
K
)
n0 − gvn0 − sn0 ,
n˙1 = f1
(
1− n
K
)
n1 − ηgvn1 + αgvn0 − sn1 ,
v˙ = b (1− α) gvn0 + bgvηn1 − gv(n0 + n1)− sv .
(19)
If we consider the case in which infected bacteria do not instantaneously die, the steady state solutions
change quantitatively, but not qualitatively. For example, consider the condition on the failure probably
bη = 1 that defines the boundary of the region where steady state solutions exist. If the infected bacteria
survive for a period of time before dying, it turns out that this condition will be replaced by bη = w where
w = µ+sµ . The dimensionless parameter w effectively rescales the time of phage release from infected cells.
As before, we can identify three classes of steady state solutions.
1. The coexistence scenario.
Here we get that
n1
n
= − α
1− α− η +
αf0((b− 1)gK − s)[
f0
(
(b− 1)gK − s)− (b− 1)gKs](1− α− η)2 γ +O(γ2) . (20)
As above, we expect that γ  1 and that α + η < 1 – under these conditions the positivity of n1
implies that the coexistence solution is not feasible.
2. The monoclonal-bacteria scenario.
Here wild type bacteria are absent:
n0 = 0 ,
n = n1 =
s
g(bη − 1) ,
gvη = f1
(
1− s
gK(bη − 1)
)
− s .
(21)
This solution is feasible when η > 1/b, a regime where failure rate is high, opposite to the situation
considered in the main text. The virus only survives because the spacer fails with a relatively high
probability. However, if the dilution is large (s > gK(bη − 1)) there will be no viruses left at steady
state because growth of virus in the bacteria is more than compensated for by loss due to dilution.
Again in this regime adding spacer loss will keep wild type bacteria alive, allowing for coexistence of
the two species of bacteria and the virus.
3. Low infection scenario.
The only scenario in which virus and both types of bacteria co-exist without spacer loss is one where
the spacer-enhanced and wild-type bacteria grow at different rates (γ 6= 0). The steady state solutions
at leading order in γ are
n1
n
= x
(0)
1 + γx
(1)
1 +O(γ
2) ,
n0 = n− n1 ,
n = K
(
1− s
f0
)
+ γx
(1)
1
bgK2(1− α− η)(f0 − s)2
f20 s
+O(γ2) ,
v = − s
[
gK(f0 − s)
(
b(1− α)− 1)− f0s]
g(1− α− η)[gK(b− 1)(f0 − s)− f0s]γ +O(γ2) ,
(22)
where the two expansion coefficients for the fraction of spacer enhanced bacteria are
x
(0)
1 =
b(1− α)− 1
b(1− α− η) −
f0s
bgK(f0 − s)(1− α− η) ,
x
(1)
1 = f0s
2 gK(f0 − s)
(
b(1− α)− 1)− f0s
bgK
[
gK(b− 1)(f0 − s)− f0s
]
(1− α− η)2(f0 − s)2
.
(23)
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The number of viruses is proportional to the relative difference in growth rates, γ, so it is different
from zero only when spacer enhanced and wild type bacteria grow at different rates.
In order to analyze the parameters where the solution is feasible, we further expand in the dilution
parameter s, and get
x
(0)
1 =
b(1− α)− 1
b(1− α− η) −
s
bgK(1− α− η) +O(s
2) , x
(1)
1 = O(s
2) . (24)
This means that for small dilution, the total bacterial population is not resource-limited, but there is
a correction due to dilution. The coexistence between bacteria and virus is controlled by the relative
difference in growth rate, γ, and the dilution, s:
n ≈ K
(
1− s
f0
+ γs
b(1− α)− 1
f0(b− 1)(1− α− η)
)
,
n1 ≈ K b(1− α)− 1
b(1− α− η) − s
gK
(
b(1− α)− 1)+ f0
f0bg(1− α− η) + γsK
(
b(1− α)− 1)2
bf0(b− 1)(1− α− η)2 ,
v ≈ −γs b(1− α)− 1
g(b− 1)(1− α− η) .
(25)
For this solution to be feasible, we need v > 0. If the spacer enhanced bacteria have a higher growth
rate than the wild type, γ > 0, this can only happen if α > 1 − 1/b, implying an unrealistically high
(close to unity) acquisition probability. The more realistic scenario occurs when the spacer enhanced
bacteria grow slower than the wild type, γ < 0. In this case, coexistence between both bacterial species
and phage can be observed, but the amount of phage is small, since it is proportional to the product
of the relative difference in growth rates and the dilution rate, both of which are typically small.
Notice that the solutions we have found are not fundamentally new. Rather, they represent small
corrections to the solutions we found without dilution. In the main text we found that coexistence
of the phage with both bacterial species was enabled by spacer loss which then also implied that
the bacterial population did not reach capacity. Here we see that dilution provides an alternative
mechanism (other than spacer loss) for these effects, but only if spacer-enhanced and wild-type bacteria
grow at different rates (γ 6= 0). Since this rate difference is measured to be small, and since dilution in
typical experiments is an order of magnitude smaller than growth rate, we can conclude that the latter
scenario for coexistence leads to small viral populations. Stochastic effects are then likely to lead to
extinction of the virus. The spacer-loss mechanism discussed in the main text can lead to more robust
viral populations at co-existence.
IV. DETAILED STEADY STATE SOLUTION FOR MULTIPLE SPACERS
In the main text, we showed the steady state values for the case of multiple spacers only when all the
growth rates were the same. Here we generalize the dynamics from eq. [6] in the main text to the case where
each spacer (i) has a different growth rate fi,
n˙0 = f0
(
1− n
K
)
n0 + κ
N∑
i=1
ni − gvn0 ,
n˙i = fi
(
1− n
K
)
ni − κni − ηigvni + αiµI0 ,
I˙0 = gvn0 − µI0 ,
I˙i = ηigvni − µIi ,
v˙ = b
(
1−
N∑
i=1
αi
)
µI0 + bµ
N∑
i=1
Ii − gv
(
n0 +
N∑
i=1
ni
)
.
(26)
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Setting the time derivatives to zero, we obtain
I0 =
g
µ
vn0 ,
Ii =
gηi
µ
vni ,∑
i ni
n0
=
b(1− α)− 1
1− bη¯ ,
(27)
where the average failure probability (η¯) is defined as in the main text, η¯ =
∑
ηini/
∑
ni (eq. [8]). Similar
to the case of a single spacer, we see that the ratio between the total number of spacer enhanced bacteria
and the number of wild type bacteria is independent of the growth rates (fi).
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Fig D. Distribution of spacers as a function of failure probability (ηi) and acquisition probability (αi). The plot was
obtained using eqs. (30) for a set of 100 spacers with failure probability below the critical value η < ηc and acquisition
probabilities chosen uniformly in two different regimes. Panel a) First regime of small overall acquisition probability
α =
∑
αi ≈ 0.1. As explained in the main text, this leads to a very homogenous population where the best spacers
are more abundant. There is a strong dependence on the failure probability, which can be seen by the presence of
closely spaced almost vertical contour lines. Panel b) Second regime of large overall acquisition probability, α ≈ 0.4.
This tends to reduce the importance of differences in failure probability as shown by contour lines spaced far apart
that bend horizontally.
By introducing the growth rate ratio (ri = fi/f0) and the average growth rate ratio
r =
∑N
i=1 rini∑N
i=1 ni
. (28)
we can now obtain the fraction of unused capacity (Fr = 1− n/K):
Fr = κ
f0
b(1− α)− 1
(1− bη¯)
(
b− 1 + (r − 1)b(1− α)− 1
1− α− η¯
) , (29)
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which generalizes eq. [8] in the main text. The remaining steady state values are given by:
n = K(1−Fr) ,
gv = f0Fr + κb(1− α)− 1
1− bη¯ ,
n0
n
=
µ(1− bη¯)
bµ(1− α− η¯) +
(
f0Fr + κ
b(1− α)− 1
1− bη¯
)
(1− η¯ − bη¯α)
,
ni
n0
= αi
f0Fr + κ b(1−α)−11−bη¯
κ
(
1 + ηi
b(1− α)− 1
1− bη¯
)
− f0Fr(ri − ηi)
.
(30)
Just as in the case when the growth rates are all equal (eq. [9] in the main text), the distribution of spacers
shows a linear dependence on the acquisition probability αi.
Fig. D shows how the fraction of the bacterial population containing a specific spacer (ni/n) depends on
that spacer’s failure probability (ηi) and acquisition probability (αi). This is shown for the case when all
the growth rates are equal (ri = 1). Compare this to Fig. 4 in the main text, which gives a different way of
looking at these results.
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